WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTCBB: NNVC) (the “Company”) reports that its lead anti-HIV drug candidate achieved a long term anti-HIV effect with a much shorter dosing regimen and a markedly lower total drug dose than HAART drug cocktail therapy in a recent animal study. The antiviral effect of the anti-HIV nanoviricide (“HIVCide™”) continued throughout the 48 days of study even though HIVCide dosing was discontinued after only 20 days.
